Global Blood Therapeutics, Inc. announced the appointment of Scott Morrison, who brings 35 years of financial experience helping life sciences companies excel from start-up, through initial product launch, to global expansion. Mr. Morrison served as Ernst & Young's U.S. Life Sciences Leader since 2002 (retired December 2015).
Global Blood Therapeutics, Inc.
Equities
GBT
US37890U1088
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |